Adam Rosenblatt, MD

Adam Rosenblatt, MD
Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Baltimore, MD

Correspondence: Adam Rosenblatt, MD, Assistant Professor, Division of Neurobiology and Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-7131; arosenba@jhmi.edu

Dr. Rosenblatt has received grant/research support from the Forest, Amarin, and NOVA Research corporations and is on the speakers’ bureaus of the Pfizer and AstraZeneca corporations.

Adam Rosenblatt, MD
Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Baltimore, MD

Correspondence: Adam Rosenblatt, MD, Assistant Professor, Division of Neurobiology and Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-7131; arosenba@jhmi.edu

Dr. Rosenblatt has received grant/research support from the Forest, Amarin, and NOVA Research corporations and is on the speakers’ bureaus of the Pfizer and AstraZeneca corporations.

Adam Rosenblatt, MD
Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Baltimore, MD

Correspondence: Adam Rosenblatt, MD, Assistant Professor, Division of Neurobiology and Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-7131; arosenba@jhmi.edu

Dr. Rosenblatt has received grant/research support from the Forest, Amarin, and NOVA Research corporations and is on the speakers’ bureaus of the Pfizer and AstraZeneca corporations.